Company news

Arvinas, Inc. news in 2023

Arvinas, Inc.'s news releases, calls and decks from 2023, newest first.

View company

Arvinas to Host Conference Call and Webcast to Discuss Vepdegestrant (ARV-471) Data Presented at 2023 San Antonio Breast Cancer Symposium and Plans to Expand Vepdegestrant Development Program

December 4, 2023

Arvinas and Pfizer Announce Interim Data from Phase 1b Trial of Vepdegestrant in Combination with Palbociclib (IBRANCE®) and Plans to Expand Vepdegestrant Development Program

December 4, 2023

Arvinas and Pfizer Announce Updated Vepdegestrant (ARV-471) Data to be Presented at the 2023 San Antonio Breast Cancer Symposium

November 27, 2023

Arvinas Announces Oversubscribed $350 Million Private Placement

November 26, 2023

Arvinas Reports Third Quarter 2023 Financial Results and Provides Corporate Update

November 6, 2023

Potential of Arvinas’ PROTAC® AR Degraders Reinforced by 11.1 months rPFS with Bavdegalutamide and Updated Positive Interim Data from Second Generation ARV-766 in mCRPC

October 21, 2023

Arvinas Gives Back to Local Greater New Haven Community in Second Annual Impact Day

October 17, 2023

Arvinas Announces Upcoming Bavdegalutamide Poster Presentation at ESMO Congress 2023

October 14, 2023

Arvinas and Pfizer Announce Upcoming Vepdegestrant (ARV-471) Poster Presentation at ESMO Congress 2023

October 14, 2023

Arvinas Reports Second Quarter 2023 Financial Results and Provides Corporate Update

August 7, 2023

Arvinas and Pfizer Awarded Innovation Passport Designation by the U.K. Innovative Licensing and Access Pathway Steering Group for Vepdegestrant, an Investigational PROTAC® ER degrader being developed in ER+/HER2- Breast Cancer

July 30, 2023

Arvinas Announces Changes to its Board of Directors

June 14, 2023

Arvinas Announces Interim Data from the ARV-766 Phase 1/2 Dose Escalation and Expansion Trial Showing Promising Signals of Efficacy in Late-line mCRPC, Including in Patients with AR L702H Mutations

June 7, 2023

Arvinas and Pfizer Announce Upcoming Vepdegestrant (ARV-471) Poster Presentations at the 2023 European Society for Medical Oncology (ESMO) Breast Cancer Annual Congress

May 7, 2023

Arvinas Reports First Quarter 2023 Financial Results and Provides Corporate Update

May 4, 2023

Arvinas to Present at the Bank of America Securities 2023 Healthcare Conference

May 2, 2023

Arvinas and Quantum Leap Healthcare Announce Clinical Study to Evaluate Vepdegestrant (ARV-471) in I-SPY-2 Endocrine Optimization Platform (EOP) Clinical Trial

May 1, 2023

Arvinas to Present at Stifel Targeted Oncology Day

April 20, 2023

Arvinas Appoints Kelly Page as Senior Vice President, Global Head of Oncology Strategy and Program Leadership

April 2, 2023

Arvinas Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update

February 22, 2023

Arvinas to Present at 41st Annual J.P. Morgan Healthcare Conference

January 3, 2023

Decks in 2023